See more : California Water Service Group (CWT) Income Statement Analysis – Financial Results
Complete financial analysis of NeuroBo Pharmaceuticals, Inc. (NRBO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NeuroBo Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sanxiang Advanced Materials Co., Ltd. (603663.SS) Income Statement Analysis – Financial Results
- Black Hawk Acquisition Corporation Rights (BKHAR) Income Statement Analysis – Financial Results
- PS Business Parks, Inc. (PSB-PZ) Income Statement Analysis – Financial Results
- Sensys Gatso Group AB (publ) (SENS.ST) Income Statement Analysis – Financial Results
- TOPTEC Co., Ltd (108230.KQ) Income Statement Analysis – Financial Results
NeuroBo Pharmaceuticals, Inc. (NRBO)
About NeuroBo Pharmaceuticals, Inc.
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 28.00K | 72.00K | 67.00K | 17.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -28.00K | -72.00K | -67.00K | -17.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 9.16M | 2.78M | 6.55M | 21.87M | 17.48M | 14.31M | 22.69M | 8.74M | 3.99M | 52.00K |
| General & Administrative | 6.73M | 8.64M | 8.75M | 7.85M | 2.70M | 8.49M | 60.00K | 5.96M | 3.18M | 214.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.38M | 0.00 | 0.00 | 0.00 |
| SG&A | 6.73M | 8.64M | 8.75M | 7.85M | 2.70M | 8.49M | 10.44M | 5.96M | 3.18M | 214.00K |
| Other Expenses | 0.00 | -83.00K | 0.00 | -1.00K | 12.15M | -178.00K | 10.44M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 15.89M | 11.42M | 15.30M | 29.72M | 20.18M | 22.81M | 33.12M | 14.70M | 7.17M | 266.00K |
| Cost & Expenses | 15.89M | 11.42M | 15.30M | 29.72M | 20.18M | 22.81M | 33.12M | 14.70M | 7.17M | 266.00K |
| Interest Income | 461.00K | 2.19K | 14.00K | 39.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 2.19M | 0.00 | 39.00K | 22.00K | 654.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.00K | 28.00K | 72.00K | 67.00K | 17.00K | 6.67M | 60.00K | -17.00K | 2.01M | -1.00K |
| EBITDA | -15.88M | -11.40M | -15.21M | -29.61M | -21.17M | -15.49M | -33.09M | -14.50M | -6.07M | -283.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -15.89M | -19.63M | -15.30M | -29.72M | -20.18M | -22.81M | -33.12M | -14.70M | -8.08M | -266.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.42M | 5.66M | 14.00K | 38.00K | -1.14M | -43.00K | -291.00K | 110.00K | -953.00K | -54.00K |
| Income Before Tax | -12.47M | -13.97M | -15.28M | -29.68M | -21.31M | -23.64M | -33.42M | -14.59M | -9.03M | -320.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -7.85M | -62.00K | -85.00K | 1.12M | 654.00K | 286.00K | -136.82K | -146.00K | 55.00K |
| Net Income | -12.47M | -6.12M | -15.22M | -29.59M | -22.43M | -23.64M | -33.42M | -14.59M | -9.03M | -320.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.46 | -19.01 | -157.85 | -437.95 | -1.03K | -166.80 | -2.42K | -1.88K | -1.28K | -45.27 |
| EPS Diluted | -2.46 | -19.01 | -157.85 | -437.95 | -1.03K | -166.80 | -2.42K | -1.88K | -1.28K | -45.27 |
| Weighted Avg Shares Out | 5.07M | 321.70K | 96.43K | 67.57K | 21.77K | 141.71K | 13.80K | 7.75K | 7.07K | 7.07K |
| Weighted Avg Shares Out (Dil) | 5.07M | 321.70K | 96.43K | 67.57K | 21.77K | 141.71K | 13.80K | 7.75K | 7.07K | 7.07K |
NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases
New Nasdaq Ticker Symbol will be MTVA CAMBRIDGE, Mass. , Nov. 18, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a strategic realignment, ahead of important clinical milestones, with...
NeuroBo Pharmaceuticals to Participate in Investor Conferences in November
CAMBRIDGE, Mass. , Nov. 13, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced participation in the following investor conferences in November: November 14: Life Science Virtual Investor Forum.
NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Reported Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity, Revealing Favorable Safety, Tolerability and Dose-Linear Pharmacokinetics $21.7 Million in Cash at End of Third Quarter E xpected...
NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
Topline Data Readout From Part 1 and Part 2 Expected in December 2024 CAMBRIDGE, Mass. , Nov. 4, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the completion of...
NeuroBo Pharmaceuticals to Participate in Investor Conferences in October
CAMBRIDGE, Mass. , Oct. 1, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that management will participate in the following investor conferences in October: October 7: H.C.
NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
Data Revealed Favorable Safety, Tolerability and Dose-Linear Pharmacokinetics (PK) Top-Line Data Readout from the MAD Part 2 Expected in the First Quarter of 2025 Planned Phase 1 Part 3 Will Evaluate Early Proof of Concept CAMBRIDGE, Mass. , Sept. 30, 2024...
NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
CAMBRIDGE, Mass. , Sept. 3, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H.
NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Successfully Completed a Financing of up to $70 Million, With $20 Million Upfront and an Additional $50 Million of Aggregate Gross Proceeds Upon the Exercise in Full of Clinical Milestone-Based Warrants $27.9 Million in Cash at End of Second Quarter...
NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
No Significant Issues Encountered During the Single Ascending Dose (SAD) Study, Allowing for Previously Reported Accelerated Start to Multiple Ascending Dose (MAD) Part 2 Top Line Data Readout from SAD Part 1 Expected in the Third Quarter of 2024, and...
NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity
Collaboration to Leverage ImmunoForge's ELP Platform Technology Which Can Increase the Half-Life of a Drug by up to 200 Times CAMBRIDGE, Mass. , Aug. 6, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic...
Source: https://incomestatements.info
Category: Stock Reports